Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Petros Pharmaceuticals, Inc.
OTC:PTPIHealthcare · Drug Manufacturers - Specialty & Generic
+3.00%$0.0031
Prev close$0.0030-13.33%Open$0.0026+18.85%Now$0.0031
Mkt Cap$131K
EV-
Float42.28M
O/S42.37M
VOL56K sh
$ Vol$163
RVOL0.39×
Inst Own-
SI0.2%
Net Cash/Sh-
Dilution
MCap$131KFloat42.28MO/S42.37M
Dilution
No press releases found for PTPI.